NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval

Earnings Call Insights: NeoGenomics (NEO) Q1 2026

MANAGEMENT VIEW

* "Total revenue for Q1 was $186.7 million, representing 11% growth year-over-year, exceeding our guidance," said (CEO Anthony Zook), alongside "Adjusted EBITDA of $9 million" and clinical revenue of "$171 million".
* Zook highlighted portfolio mix shift as a growth driver: "The 5 NGS products we launched in 2023... contributed 25% of our clinical revenue in Q1," and added that NGS revenue "grew 26%" and "now represents about 1/3 of our total Clinical revenue." He also reiterated NeoGenomics’ community position: "we enjoy a leading 25% share across diagnostics and therapy selection."
* (President & COO Warren Stone) framed the commercial strategy around workflow and access, citing interfaces and payer breadth: "We have developed over 330 interfaces, including the recently announced Epic Aura," and said published third-party research "could drive a 20% to 30% increase in test adoption per site."
* Stone described early RaDaR ST launch metrics and timing: "In late February, we announced the full clinical launch of RaDaR ST," with "detection as low as 1 ppm," and said "Approximately 29% of customers who previously used RaDaR 1.0 have ordered RaDaR ST since launch" while "34% of RaDaR ST orders received include additional NEO tests."
* "Considering our strong first quarter revenue performance and earlier than assumed MolDX approval of PanTracer Liquid in March, we are increasing our full year revenue guidance to a range of $797 million to $803 million," said (Executive VP & CFO Abhishek Jain), while reiterating adjusted EBITDA guidance.

OUTLOOK

* Jain raised full-year revenue guidance to "$797 million to $803 million, up from $793 million to $801 million previously," tying the change to "earlier than assumed MolDX approval of PanTracer Liquid in March."
* Jain kept key launch assumptions framed as modest: "no change in RaDaR ST revenue assumption, which remains in the mid-single digit millions" and "we expect PanTracer Liquid revenue to be mid-single-digit millions following MolDX approval in early March."
* On cadence, Jain said the company now suggests modeling "approximately 9% year-over-year growth in the second quarter... followed by 9% to 10% growth in the third quarter and above 10% in the fourth quarter of 2026."
* Profitability guidance language stayed unchanged: "We are maintaining and reiterating our full year 2026 adjusted EBITDA guidance of $55 million to $57 million," and Jain added, "We have taken actions to offset these pressures" from "higher freight costs and fuel surcharges due to geopolitical environment."

FINANCIAL RESULTS

* Jain reported Q1 totals of "$186.7 million" revenue and "clinical revenue of $171.2 million," plus "nonclinical" revenue of "$15.5 million" that was "a decline of 15% year-over-year."
* Drivers inside clinical were described as both price and volume: "volumes up 6% and AUP increasing 8%" year-over-year, and "Same-store revenue, excluding Pathline was $167.9 million, representing 12% growth versus the prior year period."
* On margins, Jain said "adjusted gross margin was 46%, down 80 basis points," attributing the decline primarily to "the dilutive impact of Pathline acquisition and the launch of PanTracer Liquid prior to MolDX approval" and adding, "Together, these factors represented approximately 150 basis points of headwind in Q1 '26."
* Cash and liquidity commentary included: "Cash used in operations was $8.1 million" and "We ended the quarter with total cash of $146 million," while reiterating, "Our goal continues to be free cash flow positive this year."

Q&A

* David Westenberg, Piper Sandler & Co.: asked about NGS durability and PanTracer tissue vs. liquid mix; (CEO Zook) said "we feel very good" and pointed to early PanTracer Pro traction: "we're seeing it now almost cover 10% of PanTracer volume" and "captured 15% of new users," while (President Stone) added "PanTracer Liquid but PanTracer Family as a whole is going to be a key driver for us."
* Tycho Peterson, Jefferies: challenged the guidance raise; (CEO Zook) said the raise reflected "14% clinical revenue growth" and highlighted potential upside from "PanTracer LBx" and possible RaDaR ST indication timing, while flagging "some risk... on the nonclinical side."
* Peterson, Jefferies: asked about volume as Pathline is lapped and contract exits; (CFO Jain) said "the second quarter is going to be flattish year-over-year" on volumes with "sequential growth" expected "in Q2 onwards," while referencing headwinds from "exiting this high volume, low-value contract."
* Peterson, Jefferies: asked about the 2028 convert; (CFO Jain) said, "we are actually discussing with many of the leading banks on the convert refinancing" and "our plan is to get the refinancing done in the second half of the year," adding, "We do not want to leave this open... late in the game."
* Puneet Souda, Leerink: asked about weather and what counts as NGS; (President Stone) said NGS includes "NGS for our heme cancers" and "NGS for solid tumor" and added "the 26% growth... excludes any MRD," while (CEO Zook) said weather impact "came in pretty much as we expected" with "no" expected drag into Q2.
* Subhalaxmi Nambi, Guggenheim: pressed on payer mix and gross margin accretion for liquid biopsy and RaDaR ST; (CFO Jain) gave a liquid mix snapshot as "between the Medicare... about 40%" plus "about 10 points of Medicare Advantage" and "the other 50 commercial payers," and said commercial coverage "will take some time," while adding RaDaR ST has Medicare "about 20% to 25%" and Medicare Advantage "10% to 15%."
* Daniel Brennan, TD Cowen: asked about Epic Aura impact; (President Stone) said the company "went live with our first customer earlier this month" and described a "robust pipeline" through the year, while adding upside could come if implementations accelerate and if pull-through matches third-party studies.

SENTIMENT ANALYSIS

* Analysts’ tone was mixed, with pointed risk framing around guidance credibility and reimbursement timing; Jefferies’ Peterson said, "In the past, you've gotten over your skis with raising guidance to cut later," and Guggenheim’s Nambi pressed on whether tests are "accretive to gross margins from day 1."
* Management’s tone was slightly positive in prepared remarks and more defensive/assurance-oriented in Q&A; Zook emphasized consistency ("we again delivered double-digit revenue growth") and guidance discipline ("when we issue our guide... speak with a high degree of confidence"), while Jain used confidence language on refinancing: "there will not be any challenge in terms of refinancing the convert."
* Versus last quarter, management’s confidence language appeared more catalyst-driven (MolDX approval already received for PanTracer Liquid), while analyst skepticism shifted from waiting on reimbursement (Q4) to interrogating guidance raises and unit economics (Q1).

QUARTER-OVER-QUARTER COMPARISON

* The biggest operational change from Q4 to Q1 was PanTracer Liquid reimbursement status: Q4 described LBx as "awaiting a decision" from MolDX, while Q1 guidance was raised because of "earlier than assumed MolDX approval of PanTracer Liquid in March."
* Leadership changes in the finance function were reflected in speakers: Q4 included (Chief Financial Officer Jeffrey Sherman) and introduced Jain as "incoming CFO," while Q1 featured Jain as "Executive VP & CFO" delivering "revised 2026 guidance."
* Guidance moved higher on revenue while adjusted EBITDA stayed the same; Q4 issued "$793 million to $801 million" revenue and Q1 increased it to "$797 million to $803 million" while reiterating "$55 million to $57 million" adjusted EBITDA.
* Q4 emphasized upcoming catalysts (RaDaR ST launch "by the end of this month"), while Q1 shifted to early adoption metrics ("29%" conversion from RaDaR 1.0 and "34%" of orders with additional tests) and sales scaling plans ("add roughly 25 sales resources by the third quarter").

RISKS AND CONCERNS

* Jain cited cost pressure: "higher freight costs and fuel surcharges due to the geopolitical situation," while maintaining the company "expect[s] gross margin expansion of approximately 100 basis points year-over-year in 2026" via "Lab of the Future initiatives."
* Nonclinical demand risk remained explicit: Jain said nonclinical revenue declined "primarily driven by expected softness in pharma" and added, "We believe that we are near the bottom for this business" with sequential growth expected in the back half.
* Commercial payer timing for newer products was highlighted in Q&A; Jain said commercial reimbursement for liquid biopsy "will take some time" even with "more than 300 contracts" as a starting point.

FINAL TAKEAWAY

NeoGenomics’ management emphasized Q1’s double-digit revenue growth, a continued mix shift toward higher-value NGS (now about one-third of clinical revenue), and early traction metrics from the RaDaR ST launch, while raising 2026 revenue guidance after PanTracer Liquid secured MolDX reimbursement in March. In Q&A, analysts focused on guidance-raise credibility, payer and margin dynamics for liquid biopsy and MRD, and balance sheet planning ahead of the January 2028 convert, with the company stating it expects to refinance in the second half of 2026 and remains committed to its $55 million to $57 million adjusted EBITDA outlook.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/neo/earnings/transcripts]

MORE ON NEOGENOMICS

* NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4895433-neogenomics-inc-neo-q1-2026-earnings-call-transcript]
* NeoGenomics, Inc. 2026 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4895351-neogenomics-inc-2026-q1-results-earnings-call-presentation]
* NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4870899-neogenomics-inc-neo-q4-2025-earnings-call-transcript]
* NeoGenomics Q1 2026 Earnings Preview [https://seekingalpha.com/news/4580007-neogenomics-q1-2026-earnings-preview]
* NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction [https://seekingalpha.com/news/4552762-neogenomics-outlines-793m-801m-2026-revenue-target-as-radar-st-and-pantracer-initiatives-gain]